tiprankstipranks
Trending News
More News >
Bluejay Diagnostics, Inc. (BJDX)
:BJDX
US Market

Bluejay Diagnostics (BJDX) AI Stock Analysis

Compare
111 Followers

Top Page

BJ

Bluejay Diagnostics

(NASDAQ:BJDX)

Rating:29Underperform
Price Target:
Bluejay Diagnostics' stock is heavily impacted by its poor financial performance, with no revenue and continuous losses. The technical indicators suggest a bearish trend, and valuation is challenging due to the negative P/E ratio. Improvements in equity are noted but overshadowed by the lack of profitability and revenue generation.

Bluejay Diagnostics (BJDX) vs. SPDR S&P 500 ETF (SPY)

Bluejay Diagnostics Business Overview & Revenue Model

Company DescriptionBluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
How the Company Makes MoneyBluejay Diagnostics generates revenue through the sale of its Symphony System and associated consumables. The Symphony System is marketed to hospitals, clinics, and other healthcare facilities that require rapid diagnostic testing capabilities. The company may also engage in partnerships or collaborations with other healthcare entities to expand the reach and application of its technology. Additionally, Bluejay may generate revenue from licensing its technology or entering into strategic alliances with larger diagnostic or healthcare companies. These key revenue streams, along with potential government or institutional contracts, contribute to the company's overall earnings.

Bluejay Diagnostics Financial Statement Overview

Summary
Bluejay Diagnostics faces considerable financial challenges, with no revenue generation and persistent net losses over several years. While there have been improvements in equity, the overall financial health remains weak, reflecting high risk and dependency on external financing. Stabilizing revenue and improving cash flow management are critical for future growth and sustainability.
Income Statement
10
Very Negative
The company has consistently reported zero revenue with negative net income over multiple years. The lack of revenue growth and persistent net losses indicate a significant challenge in achieving profitability. This situation reflects a high risk in the income statement.
Balance Sheet
30
Negative
The company shows a substantial improvement in stockholders' equity from negative to positive, which is a positive sign. However, the debt-to-equity ratio is unfavorable due to high total liabilities relative to equity, and the equity ratio has been fluctuating. These mixed results indicate some improvements but also ongoing financial instability.
Cash Flow
20
Very Negative
Operating and free cash flows have been consistently negative, indicating operational difficulties. Although financing activities have provided cash inflows, reliance on external financing could be unsustainable. The cash flow situation suggests significant cash management challenges.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue216.09K0.000.00249.04K0.000.00
Gross Profit54.33K0.00-780.96K48.91K-145.72K-157.04K
EBITDA-6.41M-6.70M-9.17M-8.99M-3.08M-1.04M
Net Income-7.25M-7.72M-9.95M-9.23M-3.73M-1.13M
Balance Sheet
Total Assets5.28M6.66M4.87M13.52M21.02M1.52M
Cash, Cash Equivalents and Short-Term Investments3.12M4.30M2.21M10.11M19.05M912.36K
Total Debt187.37K222.25K352.98K492.62K0.001.06M
Total Liabilities1.41M927.92K1.97M1.98M637.16K5.72M
Stockholders Equity3.87M5.73M2.89M11.54M20.38M-4.21M
Cash Flow
Free Cash Flow-6.71M-8.13M-9.02M-8.94M-4.39M-508.71K
Operating Cash Flow-6.44M-7.82M-8.31M-7.74M-4.37M-508.71K
Investing Cash Flow-271.35K-306.78K-704.17K-1.20M-23.95K0.00
Financing Cash Flow7.17M10.22M1.11M8.07K22.53M1.33M

Bluejay Diagnostics Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.62
Price Trends
50DMA
1.76
Negative
100DMA
2.75
Negative
200DMA
3.81
Negative
Market Momentum
MACD
-0.09
Negative
RSI
44.89
Neutral
STOCH
35.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BJDX, the sentiment is Negative. The current price of 1.62 is below the 20-day moving average (MA) of 1.71, below the 50-day MA of 1.76, and below the 200-day MA of 3.81, indicating a bearish trend. The MACD of -0.09 indicates Negative momentum. The RSI at 44.89 is Neutral, neither overbought nor oversold. The STOCH value of 35.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BJDX.

Bluejay Diagnostics Risk Analysis

Bluejay Diagnostics disclosed 52 risk factors in its most recent earnings report. Bluejay Diagnostics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Bluejay Diagnostics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.41B0.36-61.88%2.33%17.09%1.64%
50
Neutral
$2.99M-136.26%9.57%10.03%
43
Neutral
$3.68M-218.77%-33.67%91.72%
IVIVF
39
Underperform
$1.98M-679.99%55.17%40.47%
38
Underperform
$111.42K-800.00%-35.03%59.34%
29
Underperform
$2.42M-200.56%81.35%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
BJDX
Bluejay Diagnostics
1.72
-30.78
-94.71%
HSDT
Helius Medical Technologies
0.18
-14.30
-98.76%
VTAK
Catheter Precision
0.24
-3.26
-93.14%
IVF
INVO Fertility
0.88
-8.31
-90.42%
TIVC
Tivic Health Systems
4.15
-2.19
-34.54%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 02, 2025